Core Insights - Ascentage Pharma announced the selection of results from two clinical studies of its drug candidates, lisaftoclax (APG-2575) and alrizomadlin (APG-115), for presentation at the 2025 ASCO Annual Meeting [1][3] - The ASCO Annual Meeting is a significant event in the oncology field, attracting over 40,000 professionals globally [2] - The company aims to advance its clinical development and provide more treatment options for patients with hematological malignancies [3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on therapies for unmet medical needs, particularly in hematological malignancies [1][7] - The company has been listed on the Hong Kong Stock Exchange since October 2019 and on the Nasdaq since January 2025 [8] - Ascentage Pharma has a diverse pipeline of innovative drug candidates targeting key proteins in the apoptotic pathway and next-generation TKIs [9] Clinical Studies - A Phase 1b/2 study of lisaftoclax combined with azacitidine in patients with treatment-naïve or prior venetoclax-exposed myeloid malignancies will be presented [4] - A Phase 2 study of alrizomadlin with or without toripalimab in patients with advanced adenoid cystic carcinoma or other solid tumors will also be presented [5] Regulatory Status - Lisaftoclax and alrizomadlin are investigational drugs and are not yet approved in the U.S. [6] - Olverembatinib, another key asset, is approved in China and included in the National Reimbursement Drug List [10] - The company has received multiple Orphan Drug Designations from the US FDA and the European Medicines Agency for its investigational drug candidates [11] Partnerships and Collaborations - Ascentage Pharma has established partnerships with leading biotechnology and pharmaceutical companies, including Takeda, Merck, and Pfizer, as well as research institutions like Mayo Clinic and Dana-Farber Cancer Institute [11]